Edit |   |
Antigenic Specificity | Human Immunodeficiency Virus Type-1 p24 |
Clone | [HIV1-24/661] |
Host Species | Mouse |
Reactive Species | HIV Type 1. |
Isotype | IgG1, kappa |
Format | unconjugated |
Size | 0.02 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (Without BSA at 1mg/ml) |
Concentration | n/a |
Applications | ELISA (EIA), Immunocytochemistry (ICC), Immunofluorescence (IF) |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Specificity: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein tha |
Immunogen | Immunogen: Recombinant HIV-1 Gag p24 protein Quantity and Buffer: 0.5 ml at 200ug/ml with BSA and azide |
Other Names | [Capsid protein p24; Human immunodeficiency virus type 1 p24; HIV1gp1; HIV-1 Gag p24], [gag-pol; P04585.; MA; CA; NC; TF; p6*; IN] |
Gene, Accession # | Gene ID: 155348, NCBI: NP_057849.4, UniProt: P04585 |
Catalog # | MBS438224 |
Price | $190, $340, $340 |
Order / More Info | Human Immunodeficiency Virus Type-1 p24 Antibody from MYBIOSOURCE INC. |
Product Specific References | 1. Voltersvik, P., Bostad, L., Dyrhol-Riise, A.M., Eide, G.E., Rosok, B.I., Olofsson, J. and Asjo, B. 2006. Cystatin A and HIV-1 p24 antigen expression in tonsil- lar lymphoid follicles during HIV-1 infection and during highly active anti- retroviral therapy. J. Acquir. Immune Defic. Syndr. 41: 277-2784. |